Description
Librela is an innovative drug for the alleviation of pain associated with osteoarthritis in dogs. The medication contains a canine monoclonal antibody (mAb) which targets nerve growth factor (NGF). This inhibits NGF-mediated cell signalling which has been demonstrated to provide relief from pain associated with osteoarthritis. The product is administered by monthly injection and has been proven to reduce pain scores in dogs with osteoarthritis.
Dosage and administration
Dosage and treatment schedule
- The recommended dose is 0.5-1.0 mg/kg bodyweight, once a month.
- For dogs weighing <5.0 kg aseptically withdraw 0.1 ml/kg from a single 5 mg/ml vial and administer subcutaneously.
LIBRELA strength (mg) to be administered
|
|||||
Bodyweight (kg) of dog
|
5
|
10
|
15
|
20
|
30
|
5.0 – 10.0
|
1 vial
|
||||
10.1 – 20.0
|
1 vial
|
||||
20.1 – 30.0
|
1 vial
|
||||
30.1 – 40.0
|
1 vial
|
||||
40.1 – 60.0
|
1 vial
|
||||
60.1 – 80.0
|
2 vials
|
||||
80.1 – 100.0
|
1 vial
|
1 vial
|
|||
100.1 – 120.0
|
2 vials
|
Needles and syringes will need to be purchased separately
This is a refrigerated product and therefore will need to be sent by courier with someone available to sign for the package upon delivery. Contents must be refrigerated upon delivery.